📊 IMRX Key Takeaways
Is Immuneering Corp (IMRX) a Good Investment?
Immuneering is a pre-revenue pharmaceutical company with zero sales and significant operating losses (-$15.3M), though improving trends show operating efficiency gains. While the balance sheet is fortress-like with $47.3M cash and minimal debt, negative free cash flow of -$18.5M means the company is burning through reserves, creating execution risk dependent entirely on successful drug commercialization.
Immuneering is a pre-revenue biotech with a very strong balance sheet—ample cash, no debt, and exceptional liquidity—providing an estimated multi-year runway at the current burn rate. Profitability remains negative but losses and EPS show YoY improvement, suggesting some operating discipline. With growth reliant on clinical progress rather than revenue scaling, fundamentals support a neutral stance pending tangible pipeline milestones.
Why Buy Immuneering Corp Stock? IMRX Key Strengths
- Exceptional financial fortress: $206.5M equity with only $8.3M liabilities and zero long-term debt
- Strong cash position of $47.3M provides runway for continued R&D operations
- Improving loss trajectory: net loss decreased 8.2% YoY and diluted EPS improved 37.7%, indicating operational progress
- Outstanding liquidity (32.45x current ratio) eliminates near-term solvency concerns
- Robust cash & equivalents with no debt
- Exceptional liquidity (17.5x current ratio) and low liabilities
- Improving net loss and EPS YoY
IMRX Stock Risks: Immuneering Corp Investment Risks
- Zero revenue with no commercialized products generates existential business model risk
- Negative free cash flow of -$18.5M annually will deplete cash reserves within ~2.5 years without revenue or financing
- Pharmaceutical development carries high clinical failure rates; entire value depends on unproven pipeline success
- No revenue means zero profitability and no path to sustainability without product commercialization
- Only 1 insider filing in 90 days suggests minimal insider conviction or activity
- Zero revenue with sustained operating losses
- High cash burn may require future dilution if timelines slip
- Clinical and regulatory execution risk typical of biotech
Key Metrics to Watch
- Monthly cash burn rate trend and total cash runway duration
- Clinical trial advancement and regulatory milestones for lead drug candidates
- Timeline to first product revenue generation and market launch
- Operating cash flow trajectory toward breakeven
- Partnerships, licensing agreements, or strategic financing activities
- Operating cash flow (quarterly)
- Cash & equivalents
Immuneering Corp (IMRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 32.45x current ratio provides a solid financial cushion.
IMRX Profit Margin, ROE & Profitability Analysis
IMRX vs Healthcare Sector: How Immuneering Corp Compares
How Immuneering Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immuneering Corp Stock Overvalued? IMRX Valuation Analysis 2026
Based on fundamental analysis, Immuneering Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immuneering Corp Balance Sheet: IMRX Debt, Cash & Liquidity
IMRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immuneering Corp's revenue has declined by 86% over the 5-year period, indicating business contraction. The most recent EPS of $-2.04 indicates the company is currently unprofitable.
IMRX Revenue Growth, EPS Growth & YoY Performance
IMRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$11.5M | $-0.43 |
| Q2 2023 | N/A | -$11.5M | $-0.43 |
| Q1 2023 | N/A | -$12.9M | $-0.49 |
| Q3 2022 | $38.4K | -$6.2M | $-0.47 |
| Q2 2022 | $94.4K | -$6.2M | $-0.44 |
| Q1 2022 | $183.7K | -$6.2M | $-0.49 |
| Q3 2021 | $482.1K | -$3.2M | $-0.47 |
| Q2 2021 | $480.8K | -$3.2M | $-0.73 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immuneering Corp Dividends, Buybacks & Capital Allocation
IMRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immuneering Corp (CIK: 0001790340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMRX
What is the AI rating for IMRX?
Immuneering Corp (IMRX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 65% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMRX's key strengths?
Claude: Exceptional financial fortress: $206.5M equity with only $8.3M liabilities and zero long-term debt. Strong cash position of $47.3M provides runway for continued R&D operations. ChatGPT: Robust cash & equivalents with no debt. Exceptional liquidity (17.5x current ratio) and low liabilities.
What are the risks of investing in IMRX?
Claude: Zero revenue with no commercialized products generates existential business model risk. Negative free cash flow of -$18.5M annually will deplete cash reserves within ~2.5 years without revenue or financing. ChatGPT: Zero revenue with sustained operating losses. High cash burn may require future dilution if timelines slip.
What is IMRX's revenue and growth?
Immuneering Corp reported revenue of $0.0.
Does IMRX pay dividends?
Immuneering Corp does not currently pay dividends.
Where can I find IMRX SEC filings?
Official SEC filings for Immuneering Corp (CIK: 0001790340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMRX's EPS?
Immuneering Corp has a diluted EPS of $-0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMRX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Immuneering Corp has a SELL rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMRX stock overvalued or undervalued?
Valuation metrics for IMRX: ROE of -6.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMRX stock in 2026?
Our dual AI analysis gives Immuneering Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMRX's free cash flow?
Immuneering Corp's operating cash flow is $-18.4M, with capital expenditures of $79.9K.
How does IMRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -6.5% (avg: 15%), current ratio 32.45 (avg: 2).